-+ 0.00%
-+ 0.00%
-+ 0.00%
Lantheus wins final FDA approval for BRAVNETSA radiopharmaceutical in GEP-NETs
Share
Listen to the news
Lantheus wins final FDA approval for BRAVNETSA radiopharmaceutical in GEP-NETs
  • Lantheus won final FDA clearance for BRAVNETSA (lutetium Lu 177 dotatate) to treat adult somatostatin receptor-positive GEP-NETs.
  • FDA deemed BRAVNETSA bioequivalent, therapeutically equivalent to Novartis’ LUTATHERA, enabling substitution under the ANDA pathway.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220800PRIMZONEFULLFEED9831173) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending